How will Avanos Medical's shift to Digestive Health and Pain Management drive revenue and margin expansion through 2026?
Avanos Medical's pivot to higher-margin Digestive Health and Pain Management matters because it ends restructuring and starts capital allocation. In 2025 Avanos reported improving gross margins and plans to prioritize M&A and buybacks, signaling a focus on profitable growth.
Monitor product mix and free cash flow; if core categories grow mid-single digits and operating leverage holds, EPS can expand double digits. See the product positioning in Avanos BCG Matrix Analysis.
Where Is Avanos Looking for Its Next Wave of Growth?
Avanos is targeting its next growth wave in Digestive Health via international Mic-Key expansion and in Pain Management through Coolief chronic pain solutions, plus ASC channel penetration and adjacent product upsell.
Scaling Digestive Health with Mic-Key International Expansion
Management plans to grow the Mic-Key enteral feeding franchise by expanding premium low-profile tube penetration in Europe and Asia-Pacific, where premium penetration is below U.S. levels and rising; leadership targets 3 percent to 5 percent organic growth in this category, supported by higher ASPs and recurring consumable sales.
Pain Management Shift from Acute Pumps to Chronic Pain
Avanos is reallocating resources away from commoditized acute pain pumps into Coolief radiofrequency (RF) ablation for osteoarthritis and spinal pain, aiming to capture non-opioid therapy demand among an aging population and expand in ambulatory surgery centers (ASCs) where utilization is growing.
Product and Platform Upside via Consumables and Adjacent Devices
Upside comes from recurring consumables tied to Mic-Key and from modular Coolief platform upgrades; higher consumable attach rates and new low-profile feeding accessories can drive margin expansion and predictable revenue streams.
Most Credible Growth Driver in 2025 – 2026: Coolief Expansion into ASCs
Realistic near-term growth is Coolief adoption in ASCs and orthopedic clinics where procedures are shifting outpatient; with osteoarthritis prevalence rising, Coolief offers a clear non-opioid pathway and measurable reimbursement tailwinds likely to drive unit growth in 2025 and 2026.
Key 2025 datapoints backing the thesis: Avanos reported mid-single-digit organic revenue growth guidance for Nutrition and recurring revenue strength in enteral feeding; Coolief therapy backlog and ASC conversion metrics show higher per-case revenue versus legacy pumps. See leadership commentary and strategic focus in Mission, Vision, and Values of Avanos Company for context: Mission, Vision, and Values of Avanos Company
Avanos SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Is Avanos Building to Get There?
Avanos Medical is building an integrated tech and commercial platform: proprietary RF manufacturing from the 2023 Diros Technology acquisition, next – generation connected enteral feeding pumps, a narrowed high – value sales focus on IDNs and ASCs, and a balance – sheet reset to fund disciplined bolt – on M&A in the $50 million to $150 million range.
Expansion Priorities: Target high – volume IDNs and ASCs
Avanos is shifting commercial coverage away from broad hospital penetration to prioritize Integrated Delivery Networks and ambulatory surgery centers that drive larger recurring purchases and shorten sales cycles.
Product or Service Innovation: Intelligent enteral feeding pumps
Investment in data – connected enteral pumps aims to boost patient compliance and cut readmissions; these pumps also open subscription and services revenue streams tied to remote monitoring and consumables.
Technology and AI Initiatives: Integrated RF platform and data analytics
The Diros high – frequency radiofrequency (RF) platform, fully integrated by 2025, reduces third – party manufacturing reliance and supports a vertically integrated tech stack; data analytics on pump usage targets clinical outcomes and cost – of – care reductions.
Partnerships or Acquisitions: Bolt – on M&A discipline
With the balance sheet cleared in 2025, Avanos is seeking tuck – ins in the $50 million to $150 million range to complement Digestive Health and Pain portfolios, accelerating category expansion without large transformational deals.
Investment and Execution: CapEx, SG&A reallocation, and margin focus
Capital is being allocated to in – house RF manufacturing and connected device development while sales headcount is redeployed toward high – volume accounts; management reports improvements in gross margin from reduced outsourcing.
The Most Important Growth Build: RF platform plus connected pumps
The combined value of Diros' RF manufacturing and intelligent enteral pumps is the core 2025 initiative: it lowers COGS, raises gross margin, and creates recurring consumables and data services revenue – key drivers for Avanos growth outlook and Avanos future prospects.
Relevant metrics through fiscal 2025: the Diros integration is complete, management cites gross margin improvement versus 2024 levels, and targeted tuck – ins remain in the $50 million to $150 million band to expand Digestive Health and Pain product lines; see Sales and Marketing Strategy of Avanos Company for commercial detail Sales and Marketing Strategy of Avanos Company
Avanos Business Model Canvas
- One-time Payment
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What Could Derail Avanos's Plan?
Several material risks could derail Avanos Medical's growth outlook: fierce medtech competition, reimbursement and pricing pressure, execution shortfalls in Chronic Pain rollouts, and supply-chain or regulatory shocks that compress margins and slow revenue growth.
Softening demand in target procedures
Slower adoption of RF ablation versus steroid injections or conservative care could limit addressable market expansion and reduce Avanos revenue growth drivers. Declines in procedure volumes or longer conversion timelines would pressure the Avanos company outlook and near-term Avanos revenue guidance.
Competition and pricing pressure from larger medtech
Boston Scientific and Medtronic scale R&D and bundled interventional portfolios pose pricing and share risks; intensified rivalry could force discounts, lower selling prices, and compress gross margin below the target 58 percent threshold.
Execution and investment risk in Chronic Pain rollout
Scaling RF generator production, clinician training, and commercial coverage requires capital allocation and tight project management. Missed launches, slower clinician uptake, or higher SG&A spend would weaken Avanos growth outlook 2026 forecast and hurt Avanos stock forecast assumptions.
Regulatory, supply-chain, and reimbursement disruption
Reimbursement headwinds – payers demanding longer-term comparative data – could limit RF ablation adoption. Sourcing shocks for medical-grade plastics or RF electronics would constrain shipments and risk gross-margin erosion. Changes in FDA guidance or adverse clinical evidence would also affect Avanos future prospects and Avanos financials.
For readers tracking risks to Avanos growth, see Target Customers and Market of Avanos Company for context on procedure mix and end markets: Target Customers and Market of Avanos Company
Avanos Marketing Mix
- Complete Marketing Mix Analysis
- Effortlessly Communicate Your Business Strategy
- Investor-Ready Format
- 100% Editable and Customizable
- Clear and Structured Layout
How Strong Does Avanos's Growth Story Look Today?
Avanos Medical's growth story looks credible but muted today; financials show strong margin and cash generation, yet organic top-line acceleration is uneven. The company appears positioned for moderate expansion driven by operating leverage and capital returns rather than rapid revenue growth.
Where Growth Direction Stands
Growth direction is toward higher-quality earnings rather than fast top-line expansion. Avanos growth outlook hinges on margin expansion – 2025 adjusted EBITDA margins near 21 percent – and free cash flow north of $100 million, reducing leverage after exiting low-margin businesses.
Near-Term Signals to Watch
Near-term signals are mixed: organic revenue growth has remained around or below 4 percent in 2025, while share repurchases under the $150 million authorization and steady FCF support EPS. Management commentary and quarterly results will confirm if Chronic Pain gains traction versus incumbents.
Key Upside Potential
Credible upside: faster share gains in the Chronic Pain portfolio, successful tuck-in acquisitions that expand clinical reach, and sustained operating leverage lifting adjusted EBITDA above current levels. Each could push Avanos company outlook toward a higher valuation multiple versus peers.
Overall Growth Judgment
My judgment for 2025/2026: Avanos represents a solid value-compounding play – not a high-growth story yet. To justify premium multiples and improve the Avanos stock forecast, the firm must convert margin strength and share buybacks into sustained revenue momentum, particularly in Chronic Pain; see History and Background of Avanos Company for context: History and Background of Avanos Company
Avanos Boston Consulting Group Matrix
- Built by Experts, Trusted by Consultants
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What Is the History of Avanos Company and How Did It Evolve?
- What Is the Competitive Landscape of Avanos Company and How Does It Compete?
- How Does Avanos Company Work and What Drives Its Business Model?
- How Does Avanos Company Reach Customers and Turn Demand into Sales?
- What Do the Mission, Vision, and Core Values of Avanos Company Reveal?
- Who Are the Core Customers in Avanos Company's Target Market?
- Who Owns Avanos Company Today and Who Holds Control?
Frequently Asked Questions
Avanos is focusing its next growth wave on Digestive Health and Pain Management. The blog highlights Mic-Key international expansion, stronger recurring consumables, and Coolief chronic pain adoption in ambulatory surgery centers and orthopedic settings as the main paths forward.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.